According to a November 14, 2025 SEC filing, 5AM Venture Management, LLC, liquidated its position in Viking Therapeutics (VKTX 0.68%) as of Q3 2025. The fund sold its entire holding of 189,593 shares over the quarter, reducing its stake from 1.9% of assets under management to zero. The estimated value of the transaction was approximately $5.02 million based on the average share price for the quarter.
Lo, Standard Chartered’s Geoffrey Kendrick, that most patient of sages, beholds the carnage of Tuesday’s midnight plunge and chuckles, as if witnessing the third act of a divine comedy. “Behold!” he proclaims to his clients, “this sell-off is but a familiar specter, a ghost from the past two years, haunting us with its predictable wails!”
According to a filing with the SEC, the fund liquidated 282,313 shares, a calculated retreat from a venture that had grown increasingly elusive. The average share price for the quarter, now a mere shadow of its former self, rendered the trade’s value at $13,325,174. One might call it a rational decision, though the word “rational” sits uneasily in the presence of hope.
Both digital darlings are wobbling on their tightropes, testing crucial support levels after a market-wide tumble that left everyone’s knickers in a twist. 🎢
On November 14, 2025, Bain Capital Life Sciences Investors, LLC offloaded 122,106 shares of Pharvaris. The post-sale holding is now 3,181,275 shares, valued at $79.37 million. A quarter-over-quarter increase, mind you, despite the sale. It’s like buying a coffee, then selling it for a bit more-only with stock. My brain hurts just thinking about it.
The filing with the Securities and Exchange Commission, that most solemn of rituals, reveals the fund’s fourteenth disclosed position in Wingstop, a stake accounting for 4.45% of its U.S. equity holdings. One might wonder: what forces conspire to draw such a behemoth of capital toward a company whose stock has languished, descending 29% over the past year, its price a shadow of its former self? Is it the siren song of a discounted valuation, or the delusion of a “buy the dip” mantra, a gambit as perilous as it is common?
It appears that the US government, perhaps bored with routine oversight, recently shifted a modest $23,000 worth of WIN tokens on the Tron network. These tokens, snatched from the notorious Alameda Research two years prior, are now on the move, reminding all that even small sparks can ignite wildfires of speculation. 🚒🔥
Openledger has launched its new blockchain, the OPEN Mainnet, positioning it as the blockchain that will finally do something about the “trillion-dollar theft problem” plaguing artificial intelligence (AI). Yes, apparently, AI has been stealing more than just our jobs – it’s been swiping data left and right like a digital kleptomaniac.
Seven months into the MiCA showdown, the rules are as clear as a Steinbeck novel: you’re either in, or you’re cattle feed. By July 2025, only 53 entities had wrangled full MiCA authorizations-14 e-money token issuers and 39 crypto-asset service providers. Meanwhile, over 120 enforcement actions had lassoed non-compliant projects, and more than 250 crypto startups had postponed their European dreams due to regulatory quicksand. Even Tether, the big bull of stablecoins, got delisted for not keeping its hay in order. 🐮💨
But here’s where it gets interesting-because nothing says “party time” like a seasoned trader with a grin and a crystal ball. Enter Michael van de Poppe, who’s pretty much the weather vane of crypto optimism. He sees a silver lining in this chaos, claiming that Bitcoin’s recent dominance pattern looks eerily like 2019-a year when altcoins suddenly decided to sprout wings and steal the show. Coincidence? Perhaps not. Or maybe just a fancy way of saying “don’t panic, babies, the fun’s about to start.”